This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for NVIDIA, McDonald's & Intuit
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), McDonald's Corporation (MCD) and Intuit Inc. (INTU).
Regeneron (REGN) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed the most recent trading day at $743.75, moving -0.19% from the previous trading session.
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review
by Zacks Equity Research
Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA
Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback
by Zacks Equity Research
Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.
Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak
by Zacks Equity Research
Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.
Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.
Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.
Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.
5 Least-Hurt Biotech ETFs of the Last Week
by Sanghamitra Saha
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
by Zacks Equity Research
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
by Zacks Equity Research
Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.
Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
Sanofi (SNY) Q4 Earnings Miss Estimates, Vaccine Sales Weak
by Zacks Equity Research
Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
by Zacks Equity Research
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
Why Regeneron (REGN) Might Surprise This Earnings Season
by Zacks Equity Research
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Time to Buy Cigna or Regeneron Stock Before Earnings?
by Shaun Pruitt
Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Regeneron (REGN) Stock Moves -0.86%: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed the most recent trading day at $736.46, moving -0.86% from the previous trading session.
Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.
Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.